Insider Actions for Harrow Health Inc.
– Purchase
– Sale
1
– Number of Transactions
Date
Name
Transaction
Value
| 01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
35,179 | Derivative/Non-derivative trans. at $14.76 per share. | 519,242 |
| 01/02/2023 |
Andrew R. Boll Chief Financial Officer |
9,602 | Derivative/Non-derivative trans. at $14.76 per share. | 141,725 |
| 01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
88,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/02/2023 |
Andrew R. Boll Chief Financial Officer |
23,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 12/22/2022 |
Mark L. Baum Chief Executive Officer; Director |
25,000 | Acquisition at $13.39 per share. | 334,750 |
| 12/22/2022 |
Andrew R. Boll Chief Financial Officer |
2,500 | Acquisition at $13.54 per share. | 33,850 |
| 12/22/2022 |
R. Lawrence van Horn Director |
1,860 | Acquisition at $13.42 per share. | 24,961 |
| 12/21/2022 |
Martin A. Makary Director |
25,000 | Acquisition at $13.37 per share. | 334,250 |
| 12/14/2022 |
Opaleye Management, Inc. |
16,183 | Acquisition at $10.52 per share. | 170,245 |
| 12/14/2022 |
Opaleye Management, Inc. |
415,000 | Acquisition at $10.52 per share. | 4,365,800 |
| 09/30/2022 |
Richard L. Lindstrom Director |
40,000 | Disposition at $12.62 per share. | 504,800 |
| 09/28/2022 |
Opaleye Management, Inc. |
1,085 | Acquisition at $9.77 per share. | 10,600 |
| 09/28/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $9.77 per share. | 97,700 |
| 04/13/2022 |
Opaleye Management, Inc. |
2,832 | Acquisition at $6.76 per share. | 19,144 |
| 04/13/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $6.76 per share. | 67,600 |
| 04/12/2022 |
Opaleye Management, Inc. |
3,557 | Acquisition at $6.75 per share. | 24,009 |
| 04/12/2022 |
Opaleye Management, Inc. |
25,000 | Acquisition at $6.75 per share. | 168,750 |
| 02/19/2022 |
Andrew R. Boll Chief Financial Officer |
20,605 | Derivative/Non-derivative trans. at $7.87 per share. | 162,161 |
| 02/19/2022 |
John P. Saharek President, ImprimisRx |
25,923 | Derivative/Non-derivative trans. at $7.87 per share. | 204,014 |
| 02/19/2022 |
Andrew R. Boll Chief Financial Officer |
50,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/19/2022 |
John P. Saharek President, ImprimisRx |
50,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/28/2022 |
Opaleye Management, Inc. |
1,343 | Acquisition at $6.89 per share. | 9,253 |
| 01/28/2022 |
Opaleye Management, Inc. |
5,000 | Acquisition at $6.89 per share. | 34,450 |
